Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Fusen Pharmaceutical Co., Ltd. (1652) Stock Price & Analysis

0 Followers

1652 Stock Chart & Stats

HK$0.93-HK$0.02(-2.11%)
At close: 4:00 PM GMT+8
HK$0.8HK$0.9HK$1HK$1.1Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
HKD 0.82 - HKD 0.93
52-Week Range
HKD 0.67 - HKD 1.44
Previous Close
HKD 0.95
Volume
N/A
Average Volume (3M)
90.53K
Market Cap
HKD 698.46M
Enterprise Value
HKD 1.07B
Total Cash (Recent Filing)
HKD 87.82M
Total Debt (Recent Filing)
HKD 313.96M
Price to Earnings (P/E)
―
Beta
0.15
Next Earnings
Mar 31, 2027 (Est.)
EPS Estimate
N/A
Last Dividend Ex-Date
Jun 07, 2022
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

2025 Revenue Recovery

The strong 2025 revenue rebound indicates that demand and commercial activity recovered after the prior-year contraction. If the recovery persists, it can improve operating scale, support better absorption of fixed costs, and provide a foundation for restoring profitability over the next several quarters.

Recent Cash Generation

Positive operating and free cash flow in the two most recent years gives the company internally generated funding for ongoing operations and investment. This supports financial resilience and reduces reliance on external financing, although the durability of this benefit depends on stabilizing cash-flow performance.

Positive Equity Base

A positive equity base and relatively stable assets provide a financial cushion against operating volatility and support the company’s ability to continue serving its market. This balance-sheet foundation is a durable strength, even though increased debt and recent losses limit its overall flexibility.

Bears Say

Sustained Losses And Margin Pressure

Multi-year losses show that the business has not converted revenue into consistent earnings, while 2025 margin compression indicates weaker profitability quality. Continued losses could restrict reinvestment, reduce financial flexibility, and make the revenue recovery less valuable unless margins improve sustainably.

Higher Leverage

The increase in debt relative to equity has reduced balance-sheet flexibility compared with earlier years. Higher leverage can make it harder to absorb prolonged losses or fund growth internally, and it increases the importance of restoring operating profitability while maintaining positive equity.

Volatile Cash Flow

Although recent cash generation is positive, the sharp 2025 free-cash-flow decline and prior negative results demonstrate inconsistent conversion of operations into cash. This volatility makes funding capacity less dependable and could constrain investment or debt management if profitability remains weak.

Fusen Pharmaceutical Co., Ltd. News

1652 FAQ

What was Fusen Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Fusen Pharmaceutical Co., Ltd. lowest stock price was HK$0.67 and its highest was HK$1.44 in the past 12 months.
What is Fusen Pharmaceutical Co., Ltd.’s market cap?
Fusen Pharmaceutical Co., Ltd.’s market cap is HK$698.46M.
When is Fusen Pharmaceutical Co., Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Fusen Pharmaceutical Co., Ltd.’s earnings last quarter?
Fusen Pharmaceutical Co., Ltd. released its earnings results on Aug 31, 2026. The company reported -HK$0.021 earnings per share for the quarter.
Is Fusen Pharmaceutical Co., Ltd. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Fusen Pharmaceutical Co., Ltd. pay dividends?
Fusen Pharmaceutical Co., Ltd. pays a dividend of HK$0.004 which represents an annual dividend yield of ―. See more information on Fusen Pharmaceutical Co., Ltd. dividends here
What is Fusen Pharmaceutical Co., Ltd.’s EPS estimate?
Fusen Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fusen Pharmaceutical Co., Ltd. have?
Fusen Pharmaceutical Co., Ltd. has 739,301,000 shares outstanding.
What happened to Fusen Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Fusen Pharmaceutical Co., Ltd. reported an EPS of -HK$0.021 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Fusen Pharmaceutical Co., Ltd.?
Currently, no hedge funds are holding shares in HK:1652
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology